Renishaw Earnings Calls
| Release date | Feb 11, 2026 |
| EPS estimate | $0.91 |
| EPS actual | $0.93 |
| EPS Surprise | 1.64% |
| Revenue estimate | 469.095M |
| Revenue actual | 492.536M |
| Revenue Surprise | 5.00% |
| Release date | Feb 11, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Sep 18, 2025 |
| EPS estimate | $0.91 |
| EPS actual | $0.709 |
| EPS Surprise | -22.26% |
| Revenue estimate | 506.7M |
| Revenue actual | 506.444M |
| Revenue Surprise | -0.0506% |
| Release date | May 08, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Renishaw
Below you can see how RNSHF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | May 08, 2025 |
| Price on release | $29.92 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 02, 2025 | $29.92 |
| May 05, 2025 | $29.92 |
| May 06, 2025 | $29.92 |
| May 07, 2025 | $29.92 |
| May 08, 2025 | $29.92 |
| May 09, 2025 | $29.92 |
| May 12, 2025 | $29.92 |
| May 13, 2025 | $29.92 |
| May 14, 2025 | $29.92 |
| 4 days before | 0.0064% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0.0064% |
| Release date | Sep 18, 2025 |
| Price on release | $45.23 |
| EPS estimate | $0.91 |
| EPS actual | $0.709 |
| EPS surprise | -22.26% |
| Date | Price |
|---|---|
| Sep 12, 2025 | $45.23 |
| Sep 15, 2025 | $42.57 |
| Sep 16, 2025 | $42.95 |
| Sep 17, 2025 | $45.43 |
| Sep 18, 2025 | $45.23 |
| Sep 19, 2025 | $45.43 |
| Sep 22, 2025 | $45.43 |
| Sep 23, 2025 | $45.43 |
| Sep 24, 2025 | $45.43 |
| 4 days before | 0% |
| 4 days after | 0.436% |
| On release day | 0% |
| Change in period | 0.436% |
| Release date | Feb 11, 2026 |
| Price on release | $51.68 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Feb 05, 2026 | $51.68 |
| Feb 06, 2026 | $51.68 |
| Feb 09, 2026 | $51.68 |
| Feb 10, 2026 | $51.68 |
| Feb 11, 2026 | $51.68 |
| Feb 12, 2026 | $51.68 |
| Feb 13, 2026 | $51.68 |
| Feb 17, 2026 | $51.68 |
| Feb 18, 2026 | $51.68 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Feb 11, 2026 |
| Price on release | $51.68 |
| EPS estimate | $0.91 |
| EPS actual | $0.93 |
| EPS surprise | 1.64% |
| Date | Price |
|---|---|
| Feb 05, 2026 | $51.68 |
| Feb 06, 2026 | $51.68 |
| Feb 09, 2026 | $51.68 |
| Feb 10, 2026 | $51.68 |
| Feb 11, 2026 | $51.68 |
| Feb 12, 2026 | $51.68 |
| Feb 13, 2026 | $51.68 |
| Feb 17, 2026 | $51.68 |
| Feb 18, 2026 | $51.68 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
Renishaw Earnings Call Transcript Summary of Q4 2025
Key points for investors:
- Market outlook: Industrial metrology faces mixed demand—sensor sales into machine tools (notably Germany and Taiwan) remain weak, while systems/shop-floor metrology is a growth area. Consumer electronics improved through FY25 H2 and is expected to be more positive in FY26, but remains hard to predict. Automotive exposure is roughly 13% and defense about 5% of group sales (estimations). APAC/China seen as opportunity-rich despite competition and some commoditization in parts of the market.
- Products & innovation: Management is prioritizing new-product-led revenue growth. Recent and upcoming launches called out include Equator-X with MODUS IM (major public launch at EMO), RenAM dual-laser machine, and ASTRiA inductive encoders. Management emphasizes productivity and faster commercialization (MVP approach) to accelerate time-to-market.
- Additive manufacturing (AM): FY25 AM revenue was softer and more variable given small base and high-ticket items, but order book finished strong and defense demand is highlighted as a near-term bright spot.
- Pricing & tariffs: Management has assumed U.S. tariffs are permanent and migrated surcharges into price increases. Tariff impact is ~1% of revenue (~GBP 9m) and is being offset by higher prices rather than immediate reshoring.
- Costs & savings: A cost reduction program (including closure of drug delivery business and R&D facility consolidation in Edinburgh) is expected to deliver around GBP 24m of savings. However, pay increases (including a likely January 2026 uplift) and incremental national insurance (~GBP 3m) offset some gains. Multiple productivity initiatives (ERP rollout, logistics automation, manufacturing investments) are underway to improve margins.
- Cash & capital allocation: Net cash ~GBP 300m—Board is actively discussing deployment options (M&A, buybacks, special dividends) but no decisions announced yet. Management prioritizes reinvestment in growth and productivity while being prudent on capex.
- CapEx & working capital: CapEx guidance ~GBP 40m p.a. for the next couple of years. Working capital expected to remain tightly controlled with no material change to working-capital as % of sales.
- ERP & IT: Global 1ERP rollout is in progress (UK recently went live), costs are above the line and will continue for a few years before decreasing as rollout completes.
- FX & hedging: Forward USD hedges in place (management cites $1.27–1.28 forward rates) and they do not expect significant currency-related profit volatility for FY26 at current hedges.
- Orders & near-term demand: Order trends described as overall positive, with APAC strength, Europe weakness, and mixed Americas. Management sees encouraging trends into Q4 but remains cautious.
Sign In
Buy RNSHF